Gyre Therapeutics, Inc. (GYRE): Free Cash Flow
-$180.0K
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$180.0K | n/m | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | -$5.96M | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $17.38M | +205.3% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $5.69M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$84.59M | n/a | 2023-03-30, From 2021-01-01 |
| No annual figure between 2019-12-31 and 2021-12-31. | |||
| 2019-12-31 | -$43.68M | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | -$28.93M | n/m | 2020-02-20, From 2018-01-01 |
| 2017-12-31 | -$19.96M | n/a | 2019-03-08, From 2017-01-01 |
| No annual figure between 2013-12-31 and 2017-12-31. | |||
| 2013-12-31 | -$40.65M | n/m | 2016-03-09, From 2013-01-01 |
| 2012-12-31 | -$64.57M | n/m | 2015-03-16, From 2012-01-01 |
| 2011-12-31 | -$85.15M | n/m | 2014-03-14, From 2011-01-01 |
| 2010-12-31 | $134.99M | n/m | 2013-03-15, From 2010-01-01 |
| 2009-12-31 | -$24.47M | n/a | 2012-03-06, From 2009-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | -$180.0K | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$162.73M | n/m |
| Xencor Inc (XNCR) | 2025-12-31 | -$138.27M | n/m |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $238.50M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$2.43M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$34.53M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$13.62M | n/m |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$75.37M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $22.82M | +291.4% |
Compare GYRE, URGN, XNCR, TBPH side by side · Screen every company in Pharmaceutical Preparations ↗